Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molec…
$24.44+3.04%
报价 2026-11-06
市值
$1.17B
EV
$977.5M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -53.4%
$22.50$52.50
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| RAPPRapport Therapeutics, Inc. Common Stock | $1.17B | +3.0% | 0.0% | 0% | – | – | – | |
| KODKodiak Sciences Inc. | $6.24B | +9.1% | +1783.3% | 0% | – | – | – | |
| XNCRXencor, Inc. | $2.66B | +5.0% | +15.5% | 93.9% | – | – | – | |
| SEPNSepterna, Inc. | $2.28B | +3.2% | +94.3% | 99.4% | – | – | 16.4x | |
| NRIXNurix Therapeutics, Inc. | $1.67B | +3.1% | -34.9% | -139.4% | – | – | – | |
| ANABAnaptysBio, Inc. | $1.39B | +1.9% | -48.8% | 99% | – | 27.8x | 68.4x | |
| URGNUroGen Pharma Ltd. | $1.21B | -3.8% | +135.3% | 90.9% | – | – | – | |
| OCSOculis Holding AG | $462.4M | +9.7% | – | -2,889.4% | – | – | – | |
| PHATPhathom Pharmaceuticals, Inc. | $426.8M | +3.3% | +91.4% | 87.1% | – | – | – | |
| 同行中位数 | – | – | +91.4% | 89% | – | 27.8x | 42.4x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。